Moderna, Inc. (MRNA) is owned by a number of high-value investors. Its largest direct holder is Robert S. Langer Independent Director with 11,466,961 shares. The second-largest direct holder is Stephane Bancel Chief Executive Officer and Director, with 6,720,368 shares of the company’s stock. In third place with 2,096,530 shares of MRNA is Stephen Hoge President.
Now turning to institutional ownership of Moderna, Inc. (MRNA), FLAGSHIP PIONEERING INC. is the top holder with 58.81 million shares. The next largest fund holder of this company’s stock is FMR LLC with 12.77 million shares. In the third-place spot with 8.2 million shares is VIKING GLOBAL INVESTORS LP.
This company’s stock price was $14.51 at the previous market close, with its latest volume reaching 2,718,341. Compare that to its average daily volume of 1.56M. Given the fact that this stock has 336.84M shares outstanding, its current market value is sitting at $4.89B. Its Price to Sales ratio is 45.98, its Price to Cash Flow ratio is 4.57, and its Price to Book ratio is 3.57.
MRNA stock has achieved a 5-day range of $13.76 to $15.50, with a total performance of +2.54% during that period. Meanwhile, in the past month of trading, this stock has traded in the range of $11.54 to $15.50, generating a +2.76% change during the period. In the past three months, this stock’s price has changed by -33.53%, trading in the range of $11.54 to $22.46.
In the past 5 days, shares of MRNA have made a new high 4 times. In the last month, it has made a new high 5 times, and in the past 3 months, it has made a new high 1 time.
Now let’s turn to this public company’s earnings. For the quarter ending Jun-19, the earnings per share (EPS) was reported at -$0.41. This is a 0.03 difference compared to the consensus estimate of -0.44, amounting to an earnings surprise of -6.82%. In the previous quarter, which ended in Mar-19, the consensus estimate was -0.36, making for an earnings surprise of -9.80. For the quarter ending Dec-18, EPS was reported at -$1.78, generating a -394.44% earnings surprise.
The Net Income for the most recent full fiscal year, which ended in 12-2018, was $-384.73 million. This is compared to the prior year, where Net Income was $-255.92 million. Meanwhile, this company’s Operating Cash Flow was $-330.87 million for the year, compared to $-331.48 million in 2017. Capital Expenditures for the year were reportedly -$105.77 million, compared to -$58.4 million, and Free Cash flow was $-436.63 million compared to the prior year’s $-389.88 million.
Moderna, Inc. (MRNA) stock currently has a Financial Strength score of 6.6/10. This is due to a combination of factors, including a Cash to Debt ratio of 31.87, an Equity to Asset ratio of 0.79, a Debt to Equity ratio of 0.03 and a Debt to EBITDA of -0.07. Altman Z-Score is 6.67.
This publicly-traded company’s Profitability and Growth score is 1/10, thanks to a combination of things: an Operating Margin of -493.59, a Net Margin of -460.52, a ROE of -46.34, and a ROC of -306.69.
Shifting focus now to Valuation and Return for MRNA, this company’s Price to Tangible Book is 3.57 and its Price to Median PS Value is 0.98. Meanwhile, its Earnings Yield (Joel Greenblatt) is -13.73.